Protocol Number; CBAF312A1401
Not Applicable
Recruiting
- Conditions
- secondary progressive multiple sclerosis
- Registration Number
- JPRN-jRCT2031200377
- Lead Sponsor
- Sugimoto Toshiya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
All patients using Mayzent for the following indication for a specified post-marketing period of time
Indication: prevention of secondary progressive multiple sclerosis recurrences and prevention of physical disability progression
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Incidence of adverse events between the start of Mayzent administration and 24 months (720 days) on Mayzent<br>2. Incidence of serious adverse events between the start of Mayzent administration and 24 months (720 days) on Mayzent<br>3. Incidence of adverse reactions between the start of Mayzent administration and 24 months (720 days) on Mayzent
- Secondary Outcome Measures
Name Time Method